NeoTherapeutics Takes a Charge in Loss

NeoTherapeutics Inc., an Irvine developer of treatments for neurological and psychiatric diseases, reported a second quarter net loss of $12.3 million, or $1.29 a share, which included a $1-million noncash accounting charge related to the sale of debentures. The net loss for the prior year totaled $4.1 million, or 63 cents a share. No revenue was recorded. The company attributed the wider losses to higher expenses related to its human clinical trial for Neotrofin, a potential treatment for Alzheimer’s disease.